Elanco Expands-Renovates Elwood, Kansas, Operations
08/21/2024
The investment will include the renovation of the company’s existing facility which currently manufactures and ships its Canine Parvovirus Monoclonal Antibody and will be the flagship location for future monoclonal antibody manufacturing.
“Expanding the capabilities at our Elwood manufacturing site is a critical step toward executing the most exciting pipeline in Elanco’s 70-year history,” Elanco Manufacturing and Quality Executive Vice President Grace McArdle said. “In partnership with our Elanco research and development colleagues, this site plays a key role in delivering solutions that are transforming the way veterinarians and pet owners care for the world’s animals. We appreciate the commitment of the State of Kansas, Doniphan County, and the City of Elwood to help pets live longer, healthier, more active lives.”
Elanco Animal Health Incorporated is a pharmaceutical company which produces medicines and vaccinations for pets and livestock. The company was a subsidiary of Eli Lilly and Company, before being divested.
“Sitting in the heart of the Animal Health Corridor, Kansas is a powerhouse in this critical sector – attracting companies from across the nation and around the world,” Lieutenant Governor and Secretary of Commerce David Toland noted “Elanco is an excellent example of the top-notch employers the Kelly-Toland administration is committed to partnering with as we grow the state's economy.”
Project Announcements
Kraken Technologies Limited Plans New York City Headquarters Operations
12/29/2025
Lupin Expands Coral Springs, Florida, Operations
12/29/2025
KPPC Advanced Chemicals Expands Casa Grande, Arizona, Operations
12/29/2025
Volvo Group Plans Tacoma, Washington, Distribution Operations
12/29/2025
Alnylam Pharmaceuticals Expands Norton, Massachusetts, Operations
12/29/2025
Salvagnini America Expands Hamilton, Ohio, Operations
12/28/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025